Phase II study of adjuvant chemotherapy with gemcitabine and regional arterial infusion of nafamostat mesilate for the patients with resectable pancreatic cancer
Not Applicable
- Conditions
- Adenocarcinoma of pancreas after curative resection
- Registration Number
- JPRN-UMIN000006163
- Lead Sponsor
- Jikei University school of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Pulmonary fibrosis or interstitial pneumonia detectable on chest X-ray 2)Active infection 3)Uncontrollable heart disease and myocardial infarction within 6 months 4)Uncontrollable DM 5)Pregnant or lactation women, or women with known or suspected pregnancy 6)History of severe drug allergy 7)Active synchronous or metachronous malignancy 8)Severe complications after operation 9)No chemotherapy or radiotherapy for pancreatic cancer in the past 10)Patients who are judged inappropriate for the entry into the study by the investigater
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method